Disc Medicine (IRON) Total Non-Current Liabilities (2020 - 2023)
Disc Medicine (IRON) reported Total Non-Current Liabilities of $16.0 million for Q3 2023, up 994.47% year-over-year from $1.5 million in Q3 2022, and up 39.88% on a QoQ basis from $11.5 million in Q2 2023.
Disc Medicine (IRON) has 4 years of Total Non-Current Liabilities data on file, last reported at $16.0 million in Q3 2023.
- Quarterly Total Non-Current Liabilities rose 994.47% year-over-year to $16.0 million in Q3 2023, while the trailing twelve-month figure through Sep 2023 was $16.0 million (up 994.47% YoY) and the FY2022 annual result came in at $23.6 million, up 76.71% from the prior year.
- Total Non-Current Liabilities rose to $16.0 million in Q3 2023 per IRON's latest filing, from $11.5 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $29.9 million in Q4 2020 and bottomed at -$76000.0 in Q1 2020.
- The 4-year median for Total Non-Current Liabilities is $13.4 million (2021), against an average of $12.9 million.
- The widest annual swing landed in 2021, when Total Non-Current Liabilities soared 23659.21%; it then plunged 89.77% in 2022.
- Tracing IRON's Total Non-Current Liabilities over 4 years: stood at $29.9 million in 2020, then plunged by 55.33% to $13.4 million in 2021, then jumped by 76.71% to $23.6 million in 2022, then sank by 32.12% to $16.0 million in 2023.
- Per Business Quant, the three latest IRON Total Non-Current Liabilities figures stand at $16.0 million (Q3 2023), $11.5 million (Q2 2023), and $23.6 million (Q4 2022).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 11.03 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 42,980.09 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 95.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 110.28 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 5.87 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 7.32 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.05 Bn |
| 10 | Disc Medicine | 2.76 Bn | 2.03 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | 16.02 Mn |
| Jun 30, 2023 | 11.46 Mn |
| Dec 31, 2022 | 23.61 Mn |
| Sep 30, 2022 | 1.46 Mn |
| Jun 30, 2022 | 6.44 Mn |
| Mar 31, 2022 | 12.67 Mn |
| Dec 31, 2021 | 13.36 Mn |
| Sep 30, 2021 | 14.31 Mn |
| Jun 30, 2021 | 14.39 Mn |
| Mar 31, 2021 | 17.91 Mn |
| Dec 31, 2020 | 29.90 Mn |
| Jun 30, 2020 | 6.55 Mn |
| Mar 31, 2020 | -76,000.00 |